| Nov 7 |
Nektar Therapeutics Reports Third Quarter 2024 Financial Results
|
| Nov 7 |
Nektar releases promising phase 2 results for NKTR-255 in lymphopenia
|
| Nov 7 |
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
| Nov 6 |
Nektar Therapeutics to Participate in Upcoming Investor Conferences
|
| Nov 6 |
Nektar Therapeutics Q3 2024 Earnings Preview
|
| Nov 5 |
Nektar Therapeutics to sell Alabama facility to Ampersand
|
| Nov 4 |
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
|
| Nov 4 |
Nektar announces agreement to sell Alabama manufacturing facility and reagent supply business
|
| Nov 4 |
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama
|
| Oct 31 |
Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets
|
